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Abstract
Background: Zinc is a metal ion that is essential for growth and development, immunity, and metabolism, and
therefore vital for life. Recent studies have highlighted zinc’s dynamic role as an insulin mimetic and a cellular second
messenger that controls many processes associated with insulin signaling and other downstream pathways that are
amendable to glycemic control.
Main body: Mechanisms that contribute to the decompartmentalization of zinc and dysfunctional zinc transporter
mechanisms, including zinc signaling are associated with metabolic disease, including type 2 diabetes. The
actions of the proteins involved in the uptake, storage, compartmentalization and distribution of zinc in cells is under
intense investigation. Of these, emerging research has highlighted a role for several zinc transporters in the initiation of
zinc signaling events in cells that lead to metabolic processes associated with maintaining insulin sensitivity and thus
glycemic homeostasis.
Conclusion: This raises the possibility that zinc transporters could provide novel utility to be targeted experimentally
and in a clinical setting to treat patients with insulin resistance and thus introduce a new class of drug target with utility
for diabetes pharmacotherapy.
Keywords: Zinc ions, Skeletal muscle, Cell signaling, Glycemic control
Background
Insulin resistance (IR) is a common pathophysiological
condition in which patients present with reduced insulin
sensitivity and thus glucose intolerance, particularly in
liver, adipose tissue and skeletal muscle [1]. This has
significant implications for the patient, as they are unable
to obtain to process the required energy from glucose to
maintain cellular metabolic processes. IR is of major global
concern as it is well-established as underpinning many
chronic health conditions including type 2 diabetes mellitus
(T2DM), obesity, cardiovascular disease polycystic ovary
syndrome (PCOS), liver cirrhosis [2] atherosclerosis,
hypertension, and stroke [3]. Moreover, given that IR
usually precedes the development of T2DM and contrib-
utes to the progressive nature of this challenging and devas-
tating disease, understanding the molecular mechanisms
that lead to IR will help facilitate the development of
novel therapeutic strategies to prevent or lessen disease
progression. However, despite extensive ongoing research
into IR, its molecular mechanism(s) of action remains
largely elusive.
Recently, research on metabolic processes associated
with IR and T2DM has revealed an exciting role for the
biochemical and physiological role of zinc and the proteins
that transport zinc in cells in diseases associated with
abnormal cellular signaling [4]. Accordingly, zinc and the
proteins that transport this metal ion have emerged as
potential therapeutic targets for disease states associated
with dysfunctional metabolism. For example, zinc in the
diet and zinc transporter proteins that influence/regulate
zinc metabolism are implicated in metabolic homeostasis in
peripheral tissues (e.g. skeletal muscle and liver) that re-
spond to insulin [4].
Zinc is ubiquitous in physiological systems, albeit, within
tightly controlled parameters, and therefore suggests that
atypical levels are likely to have significant biological and
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clinical effects on disease processes. Knowing how zinc
transporter proteins and the storage of zinc in cells are in-
volved in metabolic processes implicated in IR for example,
may present opportunities to develop novel drugs targeting
these transporters to prevent or treat IR and T2DM disease
progression.
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is devastating disorder
characterised by hyperinsulinemia, hyperglycaemia, com-
promised energy metabolism and expenditure, and the
progression of chronic illness and disease. T2DM is high
complex involving both genetic predisposition and envir-
onmental factors. A major factor involved in a person’s
susceptibility to T2DM can be linked through family
history of diabetes. For example, Pacific Islander peoples
are a unique population with especially high rates of T2DM
[5]. The environment also plays a major role in the devel-
opment of IR and T2DM with inactivity and poor nutri-
tional status being two key factors [6].
Development of T2DM
The development of T2DM is preceded by IR, a disorder
associated with hyperinsulinemia, glucose intolerance
and dysfunctional energy metabolism [7]. A leading con-
cern for people with IR is the progressive failure of pan-
creatic β-cell function (a major determinant of T2DM
progression) and thus, compromised insulin secretion
[8]. T2DM occurs primarily due to pancreatic β-cell fail-
ure, including disruption of β-cell function and mass [8].
Elevated blood glucose causes the pancreatic β-cells to
produce more insulin resulting in hyperinsulinemia. Thus,
pancreatic β-cells amplify insulin synthesis as well as insulin
secretion pathways to overcome IR through an adaptive
response called β-cell compensation [9]. Consequently, the
failure of β-cells occurs in response to elevated insulin
levels and thus elevated blood glucose which results in in-
sulin insufficiency and overt diabetes. Accordingly, T2DM
patients with loss of β-cell function will cease to live a
normal life and will endure life-long pharmacological inter-
vention, often with episodes of illness from unfavourable
side-effects associated with the anti-diabetic treatments.
Therefore, prevention strategies that take advantage of this
“window of opportunity” (before β-cell failure) to prevent
or lessen disease progression would have an enormous im-
pact on the health and wellbeing of our communities.
Current drug treatments for T2DM
There are a range of medicines available to manage and
treat IR and T2DM, however, side effects of these drugs
have always been a foremost challenge in relation to the
goal of pharmacotherapy [10] (Table 1). Yet, treatments
for IR have not advanced significantly in the last few
decades because of the inadequate knowledge about the
pleiotropic effects that these drugs have on specific
molecular targets [11]. Therefore, finding strategies to
increase the efficacy and safety of therapeutic treatment for
IR and T2DM is highly critical. In this context, research
over the last decade has suggested a role for zinc in the
treatment of T2DM [12]. For example, lowered zinc
concentrations have been identified in some patients
with T2DM [13] and zinc supplementation appears to
improve the effectiveness of oral hypoglycaemic agents,
decreasing blood glucose, triglycerides and inflammation
in some patients [14]. However, many of these kinds of
studies are not consistent in their findings and adds fur-
ther complications in determining a role for zinc in these
processes. Thus, it will be important to look at the role of
zinc transporters and how they transport zinc within a
cellular context during disease progression.
Zinc
Zinc is an essential trace element that is found in all
parts of the body including the fluids and secretions,
tissues and organs. Zinc is one of the most abundant
trace metals (next to iron) in the human body, con-
taining approximately 2–4 g [15]. The concentration
of zinc in tissues is highest in the prostate (approxi-
mately 200 μg/ml), followed by the pancreas (approxi-
mately 40 μg/ml) and then muscle (approximately
50 μg/ml). In human plasma, there is approximately
14–16 μM of total zinc that is distributed to cells and
subcellular organelles [15]. In multicellular organisms,
almost all zinc is intracellular with the nucleus har-
bouring approximately 30–40%, the cytoplasm, organ-
elles and specialised vesicles approximately 50%, and
the cell membrane has about 10% [12]. Under normal
cellular conditions there is no free zinc and therefore,
the compartmentalization and distribution of cellular
zinc is highly important and tightly controlled so that
zinc homeostasis is maintained with an appropriate
cellular concentration and physiological range. This is
achieved by a family of zinc transporter proteins and
metallothioneins [16, 17].
Table 1 Some common anti-diabetic therapies and their side
effects
Current Therapies Side Effects
Metformin (dimethylbiguanide) Gastrointestinal intolerance and
side effects [76, 77].
Sulphonylureas Hypoglycaemia risk, weight gain
[78], cardiovascular disease [79].
Incretin-based therapies Arrhythmia [80], pancreatitis [81].
Thiazolidinediones Risk of heart failure [82].
Dipeptidylpeptidase-4 inhibitors Heart failure [83].
Sodium-coupled glucose co-
transporter (SGLT-2) inhibitors
Dehydration and urinary infections
in elderly patients [84].
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Metallothioneins and zinc transporters
Two families of zinc transporter proteins and zinc buffering
proteins play a critical role in the influx, efflux, buffering
and compartmentalization of zinc. These are the zinc trans-
porters (ZnT proteins and Zrt/Irt-like ZIP proteins),
and the intracellular zinc-binding metallothionein (MT)
proteins [18]. MT proteins are a group of soluble low
molecular weight metal binding proteins that buffer
and translocate zinc within the cytosol [19]. The ZIP
and ZnT1 zinc transporters belong to a family of trans-
membrane proteins that control zinc movement and
thus zinc concentrations in cells. The ZnT family mem-
bers (ZnT1–10) are involved in depleting cytosolic zinc by
moving this metal ion into intracellular organelles or from
the extracellular space while the ZIP family members in-
crease cytosolic zinc by transporting this metal ion from
outside the cell or from intracellular organelles (Fig. 1).
ZIP transporter family
The original member of the ZIP family of zinc transporters
was identified in Saccharomyces cerevisiae (designated
ZRT1) based on an amino acid sequence similarity to
that of Irt1p, an Fe(II) regulated transporter from
Arabidopsis thaliana [20, 21]. Consistent with the pro-
posed role of ZRT1 in zinc uptake, zinc uptake was
increased when this transporter was overexpressed in
yeast cells. Similarly, a mutation that disrupted the func-
tion of ZRT1 led to reduced levels of zinc uptake and poor
cellular growth in the mutant yeast strain [21].
The ZIP family of zinc transporters have a predicted
eight transmembrane domain (TMD) structure and this
is orientated with the N- and C-terminal facing the extra-
cytosolic region. Many of these members have a predicted
long histidine-rich loop region (HXn, n = 3–5) situated
between TMD 3 and TMD 4 that is suggested to serve as
a zinc-binding site (Fig. 2) [22, 23]. In mammals, there are
at least fourteen ZIP transporters that have critical roles in
the transport of zinc into cytoplasm from extracellular
sources and intracellular storage compartments such as
the Golgi apparatus and endoplasmic reticulum, when the
cytosolic zinc is depleted. The ZIP transporters are regu-
lated by intracellular and extracellular zinc concentrations,
and hormones and cytokines. They are also expressed in
several tissues and cell types and their proteins are local-
ized to specific subcellular compartments and have been
extensively reviewed elsewhere [24].
ZnT transporter family
The ZnT zinc transporters are a large family that include
members with similar structural homology to bacteria,
fungi, nematodes, insects, plants and mammals [25]. This
family is predicted to have six transmembrane domains
(TMDs) with a histidine-rich loop region between TMD 4
and TMD 5 (Fig. 2). The original mammalian ZnT was
identified from a rodent cDNA library and was shown ex-
perimentally to confer resistance to zinc toxicity in baby
hamster kidney cell lines [26]. Since the discovery of
ZnT1, nine other members have been identified (desig-
nated SLC30A1–10). ZnTs are implicated in the transport
of zinc into subcellular organelles and from the cytosol
through the plasma membrane into the extracellular space
[25]. Like the ZIPs, the ZnTs are regulated by intracellular
and extracellular zinc, hormones, and cytokines and are
extensively reviewed elsewhere [24].
Zinc, zinc transporters and cellular signaling: A prelude to
cell signaling and insulin resistance
Changes in zinc compartmentalization and availability in
cells is typically detected and regulated by the intrinsic
control of zinc transporter proteins. The cellular homeosta-
sis of zinc is highly complex and there are several highly
significant reviews on these processes [12, 15, 16, 27–30].
Accordingly, this section of the review aims to delineate the
mechanisms by which zinc, and zinc transporters contrib-
ute to cell signaling and how these processes might provide
insights into the molecular mechanisms implicated in
disease processes such as insulin resistance and type
2 diabetes.
Zinc mimics the action of several molecules implicated
in cellular metabolism including hormones, growth factors,
and cytokines, and given the large number of mammalian
zinc transporters that regulate zinc homeostasis, it is not
surprising that this metal ion has been highlighted as a
leading signaling molecule like calcium. Two modes of
zinc signaling have been described. These are 1) early
Fig. 1 Cellular and subcellular localization of zinc transporters ZIP
and ZnT. The primary localization of ZIP transporters (red arrow
heads) and ZnT transporter (purple arrows) is shown representing
the direction of zinc transport. Figure was produced using
Smart Servier Medical Art, http://smart.servier.com/ and adapted
from Kimura and Kambe (2016) [22]
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zinc signaling (EZS) and, 2) late zinc signaling (LZS).
EZS, is a process that is independent of gene transcrip-
tion and results in rapid changes in intracellular levels
of zinc that occurs in minutes (the ‘zinc wave’ response)
through the triggered release of zinc from subcellular
organelles into the cytosol [31]. This phenomenon was
first shown in studies in mast cells where an extracellular
stimulation of these cells with the high affinity IgE re-
sulted in a rapid increase in intracellular zinc from the
endoplasmic reticulum within minutes [32]. LZS can
also be triggered by extracellular stimuli but involves
transcriptional-dependent changes in genes and thus
proteins that are involved in zinc homeostasis such as
storage proteins or transporters [33]. The importance
of these two mechanisms of EZS and LZS highlight the
diverse roles that this metal ion plays in processes that re-
quire rapid signals (such as metabolism) and more long-
term functions such as cell differentiation and cell growth.
The defining role of zinc as a signaling molecule was
shown in early studies in rat adipocytes where zinc could
stimulate lipogenesis, independent, and additive to that
of insulin [34]. Similarly, in rat adipocytes, zinc activated
cAMP phosphodiesterase and the mobilization of glucose
transporters to the plasma membrane, independent of
insulin receptor kinase activity [35]. Since these studies
implicating zinc as a signaling molecule, there is increas-
ing evidence suggesting zinc acts in extracellular signal
recognition [32], second messenger activity [36], protein
kinase activity [37], protein phosphorylation [38], and
transcription factor regulation [39]. These studies clearly
highlight the role of zinc in signaling processes that are
also associated with insulin-mediated metabolism.
The mechanisms of the insulin-mimetic action of zinc
have been delineated in several studies however it is still
unclear how these processes occur. One well-established
mechanism of zinc action on cellular signaling events
occurs through the inhibition of protein tyrosine phosphat-
ase 1B (PTP1B). PTP1B functions as a negative regulator of
insulin and leptin signaling transduction pathways [40].
Thus, the inhibition of PTP1B by zinc ions can prolong the
insulin signal through the insulin receptor. Similarly, the
ability of zinc to modulate glucose transport, glycogen syn-
thesis, lipogenesis, to inhibit gluconeogenesis and lipolysis,
and to regulate key elements of the insulin signaling
pathway [41] suggests that this metal ion could provide
therapeutic insight or utility in the management and/or
treatment of insulin resistance. This is an interesting
notion in a clinical context since patients that are insulin
resistance have a “blunted” response to insulin and subse-
quent downstream cellular signaling responses. Therefore,
the activation of cellular insulin signaling cascade that is
critical to achieve glycemic control might involve zinc.
However, the question remains as to whether zinc inde-
pendently activates critical molecules involved in cellular
signaling in the absence of insulin or whether zinc requires
insulin for these processes.
Zinc transporters, cellular signaling and insulin resistance
Given the well-established role of zinc transporters in
mediating the critical control of zinc homeostasis in
cells, it will be important to further delineate their func-
tion in cell signaling events in the context of metabolic
control. Currently, information is limited to what role the
zinc transporters might play in cell signaling events in the
context of insulin resistance. Therefore, extrapolation of
studies from other cellular systems or disease states that
have identified zinc transporters and thus zinc flux in
facilitating cell signaling events might prove useful.
Studies accessing the role of zinc transporters in cellular
signaling found that the zinc transporters ZnT5 and ZnT7
are responsible for loading zinc to alkaline phosphatases
(ALPs) in the biosynthetic-secretory pathway in chicken B
Fig. 2 Predicted structure of the zinc transporters ZIP and ZnT. ZIP transporters are predicted to have eight transmembrane domains (TMDs) with
a long histidine loop between TMDs 3 and 4. The ZnT transporters are predicted to have six TMDs with a histidine loop between TMDs 4 and 5.
Figure was produced using Servier Medical Art, http://www.servier.com
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lymphocyte-derived cells [42]. These authors noted that
mutant cells lacking both ZnTs resulted in a marked loss
in ALP activity and this activity could be restored by over-
expressing both ZnT5 and ZnT7. Similarly, the coopera-
tive activity of ZnT1, ZnT4 and metallothioneins are
required for the full activation of alkaline ALP in the
early-secretory pathway [43]. Accordingly, the above stud-
ies demonstrate that ALP can be activated by the ZnT
family of zinc transporters and therefore aid in the control
of numerous cellular events.
In other studies, ZnT1 can regulate Raf-1 enzymatic
activity in Xenopus oocytes and cultured mammalian cells
[44]. Raf-1 plays a critical role in signal transduction in
eukaryote cells where it phosphorylates and activates
MEK1, a protein threonine and tyrosine kinase that acti-
vates the MAPK family members ERK1 and ERK2 [45].
ZnT1 was shown to bind to the amino end of the Raf-1
protein and promote kinase activation. Moreover, increas-
ing the concentration of intracellular zinc inhibited
Ras-mediated signaling through zinc blocking the abil-
ity of ZnT1 to bind Raf-1 [44] suggesting that Raf-1
activity requires functional ZnT1.
Of the ZIP transporters, ZIP14 is important in G-protein
coupled receptor (GPCR)-mediated signaling through the
maintenance of intracellular cAMP levels via suppression
of phosphodiesterase activity [46]. In these studies, fasting
gluconeogenesis is impaired in the livers of ZIP14 knockout
mice which was attributable to changes in GPCR signaling
processes. Similarly, in ZIP14 knock-out mouse chondro-
cytes, parathyroid hormone-related peptide (PTHrP)-
mediated c-fos activity was significantly reduced. PTHrP
stimulates the phosphorylation of cAMP response element-
binding protein (CREB) which in turn induces the tran-
scription of c-fos [47].
Studies in MCF breast cancer cell lines have identified
that ZIP7 is essential in the redistribution of zinc from
intracellular stores to the cytoplasm and subsequent zinc-
induced inhibition of phosphatases [36]. Moreover, ZIP7
knock-down in these cells prevented the zinc-induced acti-
vation of epidermal growth factor receptor (EGFR), insulin-
like growth factor-1 receptor (IGF-1R), and protein kinase
B (AKT); key molecules implicated in cellular metabolism.
In fact, ZIP7 has been coined the “gatekeeper” of cytosolic
release from the endoplasmic reticulum (ER) and Golgi
apparatus [48]. ZIP7 is phosphorylated by CK2 in MCF-7
cells and this activation leads to the “gated” release of zinc
from the ER and the subsequent activation of multiple
downstream signaling pathways including AKT and extra-
cellular signal-regulated kinases 1and 2 (ERK1/2) [48].
ZIP7 is essential for the proliferation of intestinal epithe-
lial cells and mice lacking this transporter in intestinal epi-
thelium have massive apoptosis of transit-amplifying cells
due to increased endoplasmic reticulum stress (ER) [49].
Similarly, studies identified that the phosphorylation of
ZIP7 was increased in cardiomyocytes under hypergly-
cemia conditions and was implicated in driving ER
stress [50]. Given that ZIP7 facilitates the release of
zinc from the ER [48] and ablation of ZIP7 in mesen-
chymal stem cells led to the accumulation of zinc in
the ER and subsequent ER dysfunction [51], it is plaus-
ible that ZIP7 could also be implicated in ER stress in
type 2 diabetes. Undeniably, ER stress and the dysregu-
lation of ER function in pancreatic beta cells are central
in the pathogenesis of diabetes [52].
Previously we have identified a role for ZIP7 in glycemic
control in skeletal muscle [53]. Skeletal muscle acts as a
major reservoir for zinc containing approximately 60% of
total whole-body zinc [54]. Knock-down of ZIP7 in C2C12
mouse skeletal muscle cells led to a significant reduction in
several genes and proteins involved in glucose metabolism
including the insulin receptor (Ir), insulin receptor sub-
strates 1 and 2 (Irs1 and Irs2), the phosphorylation of Akt,
glucose transporter Glut4, and glycogen branching enzyme
(Gbe) [53]. These data suggest that ZIP7 controls glucose
metabolism via the phosphorylation of Akt and Glut4
mobilization (Fig. 3). It is not clear if reduced ZIP7 and thus
reduced zinc levels leads to changes associated with the
phosphorylation status of the insulin receptor substrates
directly, or if reduced ZIP7 leads to inhibition of insulin
receptor signaling via binding of PTP-1B. Studies have
identified that the ZIPs play a major role in regulating cyto-
solic zinc homeostasis and insulin secretion [55]. In these
studies, it was suggested that the zinc transporters ZIP6
and ZIP7 may have a role in insulin secretion in pancreatic
beta cells via alterations in cytosolic and/or subcellular
organelle-specific zinc pools. The down regulation of these
transporters via knock-down studies led to a significant
reduction in glucose-stimulated zinc uptake and oxidative
stress in mouse islet cells [55]. These authors speculate that
reduced expression of ZIP6 and ZIP7 may disrupt zinc
homeostasis and thus produce defects in insulin secretion
and beta cell viability that could potentially lead to the
development of diabetes.
Recent studies have shown a relationship with ZIP13 and
beige adipocyte biogenesis and thermogenesis [56]. In
primary white preadipocytes isolated from white fat from
ZIP13 null mice, there was a slight increase in common
white fat genes but a significant increase in the gene expres-
sion of brown-fat specific genes and suggests that this trans-
porter is implicated the inhibition of beige fat differentiation
[56]. Moreover, these authors demonstrated that ubiqui-
nated C/EBP-β was decreased in ZIP13 null mice. C/EBP is
a major regulator of adipogenesis through the activation of
genes essential for mitotic clonal expansion and thus, ter-
minal adipocyte differentiation [57]. Accordingly, these stud-
ies suggest that ZIP13 deletion promotes beige adipocyte
production and is associated with increased exergy expend-
iture, reduced diet-induced obesity and insulin resistance.
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ZIP14 has been identified as a critical route for non-
transferrin bound iron (NTBI) uptake into liver and pan-
creatic acinar cells and is essential for the development of
liver iron overload in hemochromatosis [58]. Diabetes is
frequently associated with hemochromatosis and patients
with type 2 diabetes present with high ferritin levels which
correlate with diabetic retinopathy [59]. Similarly, ZIP14
knock-out mice have enlarged pancreatic islets, low
grade inflammation, and subsequent hyperinsulinemia
and increased body fat which are characteristic of type
2 diabetes [60].
Do the zinc transporters and zinc signaling play a role
in insulin resistance and the progression of type 2
diabetes?
Zinc plays a major role in many aspects of cell signal-
ing events in several physiological and pathophysio-
logical processes. While it is well established that at
least one zinc transporter (ZnT8) is critical for the
compartmentalization, structure and secretion of insu-
lin in beta cells of the pancreas [30], there is little
information about the other family members in this
context. Nonetheless, given the important role that
zinc transporters play in delivering bioactive zinc to
extracellular, cytosolic and subcellular milieu, and the
action of this metal ion on cell signaling events, it is
highly tempting to speculate that aberrant storage and
release of zinc will result in unfavorable processes
associated with insulin signaling and glycemic control.
ZnT8 and type 2 diabetes
Zinc is critical for the physiological role of insulin in the
form of storage in the secretory granules of the pancreas
as an inactive zinc-insulin hexamer [61, 62]. When the
zinc-insulin hexamer is released into the blood circulation,
a change in pH drives the dissociation of the complex into
a bioactive monomer of insulin [63]. The zinc transporter
that initializes zinc movement into insulin granules of the
pancreatic β-cells is ZnT8. In fact, this transporter is al-
most exclusively localized in pancreatic β-cells and it is
critical for the synthesis, storage and action of insulin [64].
Genome-wide association studies (GWAS) have discov-
ered that a nonsynonymous single nucleotide polymorph-
ism (SNP) in ZnT8 (rs13266634) encodes a C→T base
substitution resulting in a change in the coded protein
(p.Arg325Trp) and the production of two protein variants
R and W of which the C allele (R variant) is associated with
susceptibility to type 2 diabetes [65]. The frequency of the
diabetes risk R allele is 91.5%, 71.7% and 56.7% in Africans,
Europeans, and Asians, respectively [66]. Moreover, the
corresponding at-risk R325 variant had reduced zinc trans-
porter activity compared to the W325 ZnT8 in pancreatic
beta-cell lines. Therefore, carriers of the R325 variant may
have compromised packaging of insulin in pancreatic beta-
cell granules [67]. In studies of 846 European individuals,
each of whom had a parent with type 2 diabetes, it was
demonstrated that homozygous carriers of the major C
risk-allele variant had compromised pancreatic β-cell insu-
lin secretion following an intravenous glucose load [68]. It
was suggested by these authors that the function and/or
Fig. 3 Potential role of ZIP7-mediated glucose metabolism in skeletal muscle. The ZIP7-gated release of zinc from the Golgi apparatus
and/or the endoplasmic reticulum activates the phosphorylation of AKT and the subsequent mobilization of the glucose transporter
GLUT4 which in turn brings glucose into the cytosol. Zinc also inactivates the negative regulation of insulin signalling, PTP-1B which
allows the insulin signalling cascade process. The role of zinc activation of insulin receptor substrates (IRS) is not known (dashed lines)
Norouzi et al. Journal of Biomedical Science  (2017) 24:87 Page 6 of 10
production of ZnT8 in carriers of the C risk allele is re-
duced and therefore likely to contribute to compromised
pancreatic beta-cell function.
Although GWAS studies have been successful in identi-
fying variant ZnT8 alleles, it does not necessarily imply
that the risk allele has a direct pathophysiological effect
on beta-cell insulin secretion. A Meta-Analysis of Glucose
and Insulin-related traits Consortium (MAGIC) was
recently formed to conduct large-scale meta-analyses of
genome-wide data for continuous diabetes-related traits
in non-diabetics [69]. Meta-analyses were performed on
approximately 2.5 M directly genotyped or imputed
SNPs from twenty-one GWAS that were informative
for fasting glucose (FG), fasting insulin (FI) and, pan-
creatic beta-cell function (HOMA-B) and insulin resist-
ance (HOMA-IR) in non-diabetic participants [69]. It
was identified that the risk allele for ZnT8 was associ-
ated with higher FG levels and an increase in two-hour
glucose response in non-diabetics. Although these studies
identified several genetic glycemic risk loci for type 2 dia-
betes, including ZnT8, not all loci are associated with
pathological levels of glucose and type 2 diabetes risk.
More recent studies that sequenced approximately
150,000 individuals across five ancestry groups reported
twelve rare protein-truncating mutations in ZnT8 which
together explain a 65% reduced risk of developing type 2
diabetes [70]. It was found that a nonsense variant en-
coding (c.412C→T, p.Arg138*) heterozygosity yielded a
53% reduction in type 2 diabetes risk. Similarly, hetero-
zygosity for the variant encoding p.Lys34Serfs*50 which
is predicted to cause a frameshift and loss of all six
ZnT8 transmembrane domains was associated with an
80% reduction in type 2 diabetes risk.
Recently, studies aimed to delineate the effect of dietary
factor interactions with ZnT8 polymorphism (rs13266634)
and the risk of developing metabolic syndrome found a sig-
nificant interaction among omega-3 fatty acid consumption
and ZnT8 in the context of metabolic syndrome, dyslipid-
emia, and abdominal obesity [71]. Participants with the CC
genotype benefited more from the consumption of omega-
3 fatty acids than carriers of the CT +TT genotypes. Car-
riers of the CC genotype had reduced risk of developing
these disease states with increased consumption of omega-
3 fatty acids. Moreover, the risk of abdominal obesity in the
CT +TT genotype groups increased significantly with salty
snack consumption but not in the CC homozygote carriers.
Studies to investigate the role of ZnT8 and glucose
homeostasis has been established with ZnT8 null mouse
models with global deletion of ZnT8 or pancreatic beta-
cell specific ZnT8 deletion [72]. Most models resulted in
impaired or unaltered glucose tolerance, however in
ZnT8-depleted beta cells insulin granule abnormalities
were observed, and this was concomitant with a loss of
zinc release from secretory granules [73]. Similarly, ZnT8-
specific deletion in beta cells resulted in reduced periph-
eral insulin concentrations despite an unexpected increase
in insulin secretion from isolated ZnT8-depleted islets
[74]. These authors suggest that secreted insulin from the
pancreas in the ZnT8 knock-out mouse suppresses hep-
atic insulin clearance and dysregulation of this process
could play a role in the pathogenesis of type 2 diabetes. A
recent study [75] revealed ZnT8 deletion in mouse beta-
cells resulted in a significant impairment in zinc release,
normal or increased insulin secretion and subsequent im-
pairment in glucose tolerance. Moreover, transgenic mice
that overexpressed ZnT8 in beta cells showed a significant
improvement in zinc release, lower levels of insulin secre-
tion and improved glucose tolerance [75].
Given the pancreatic tissue-specificity of ZnT8 there is
potential for this transporter to be amendable to therapy
in the treatment of diabetes. However, targeting ZnT8 in
the treatment of diabetes could prove to be highly com-
plex. Although results from ZnT8 null mice suggest that
increasing ZnT8 could improve insulin secretion and
glycemic control, loss of function mutations in ZnT8
suggest a protective role for this transporter in type 2
diabetes. While ZnT8 plays a critical role in insulin
physiology, and over the last decade or so this trans-
porter has been given much attention for its role in dia-
betes, other zinc transporters have not had the same
focused attention until recently. Apart from the many
studies on zinc signaling in cells and the insulin-mimetic
action of zinc, it is unclear which zinc transporters are
involved in initiating these signaling processes. Clues
from studies on the role of ZIP7 as the “gate-keeper” of
zinc release from the Golgi apparatus [48] and subse-
quent ZIP7-mediated cell signaling events in skeletal
muscle [49] no doubt place this transporter in an im-
portant position for further studies. Identifying how the
zinc transporters are implicated in zinc signaling events
that are amendable to insulin signaling processes in in-
sulin resistance may help elucidate novel therapeutic op-
tions for the treatment of early diabetic symptoms and
thus the long-term management of this disorder and as-
sociated type 2 diabetes.
Conclusion
Zinc is an essential metal ion that is ubiquitous in many
metabolic and physiological processes. The emerging
role of zinc as an insulin mimetic in maintaining cellu-
lar function suggests that atypical levels, and aberrant
compartmentalization, transport and storage of zinc
will have biological effects that could be amendable to
clinical intervention. Although current understandings
on the role of zinc transporters in insulin resistance is
not available, and this knowledge is only just emerging
in type 2 diabetes, it is clear from studies on ZnT8 that
this family of transporters has utility for the development
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of novel diabetic therapies. While ZnT8 plays a significant
role in insulin biology and therefore represents an attract-
ive target for diabetes therapy, the other members of the
zinc transporter family in diabetes are less defined. How-
ever, we can speculate from the information presented in
this review that the other transporters are involved in pro-
cesses that facilitate insulin signaling and glycemic control
and therefore could offer exciting new targets that are
amendable to therapeutic intervention in the treatment of
diseases associated with insulin resistance and type 2
diabetes.
Endnotes
1For brevity, the terms ZIP and ZnT will be used
throughout.
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